Intellia Therapeutics Rises on FDA Priority Review for CRISPR Treatment

Key Facts

1Intellia's lonvo-z treatment received FDA Priority Review with a target decision date set for March 10, 2027.

2Wedbush analyst David Nierengarten increased the price target for NTLA to $13.00.

3The company secured a $400 million non-dilutive loan facility from OrbiMed to support its potential U.S. launch.

In a move reflecting the accelerating pace of innovation in the biotech sector, Intellia Therapeutics' lonvo-z treatment has received FDA Priority Review, with a target decision date set for March 10, 2027. This acceptance of the Biologics License Application (BLA) shortens the regulatory timeline for the potential CRISPR-based therapy for Hereditary Angioedema. Additionally, the company secured a $400 million non-dilutive loan facility from OrbiMed to provide financial flexibility for its potential U.S. commercial launch.

Per market data, analysts have responded positively to these catalysts, with Wedbush analyst David Nierengarten increasing the price target for NTLA to $13.00. This revision underscores growing confidence in the company's clinical pipeline and its ability to fund operations without diluting existing shareholders, thanks to the newly secured non-dilutive financing structure.

NTLA shares stood at $12.74 at close on September 8, 2026, having reached a day high of $12.89. Investors are now watching for a potential test of the $13.00 resistance level set by analysts; however, the upcoming economic calendar shows no major sector-specific catalysts over the next week, leaving the focus on Intellia's internal regulatory progress.